![ASCO GUIDELINES Bundle - Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy ASCO GUIDELINES Bundle - Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy](https://content.cdntwrk.com/files/aT0xNDc1NDQ0JnA9OCZ2PTEmY21kPXYmc2lnPTlkOWZmZWJhYTQ2YWUxNzg3MzcyMTEyY2ZiYzUwZTA3/-w-450-80.jpg)
ASCO GUIDELINES Bundle - Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy
![Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer | Journal of Clinical Oncology Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.20.02063/asset/images/large/jco.20.02063t3.jpeg)
Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer | Journal of Clinical Oncology
![Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer - ScienceDirect Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204518303486-gr5.jpg)
Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer - ScienceDirect
![Frailty assessment in the care of older people with haematological malignancies - The Lancet Healthy Longevity Frailty assessment in the care of older people with haematological malignancies - The Lancet Healthy Longevity](https://www.thelancet.com/cms/asset/5db32531-eec2-4204-a855-25ad44006d79/gr1.jpg)
Frailty assessment in the care of older people with haematological malignancies - The Lancet Healthy Longevity
![Prospective comparison of the value of CRASH and CARG toxicity scores in predicting chemotherapy toxicity in geriatric oncology Prospective comparison of the value of CRASH and CARG toxicity scores in predicting chemotherapy toxicity in geriatric oncology](https://www.spandidos-publications.com/article_images/ol/18/5/ol-18-05-4947-g01.jpg)
Prospective comparison of the value of CRASH and CARG toxicity scores in predicting chemotherapy toxicity in geriatric oncology
![Oncologists' perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer - ScienceDirect Oncologists' perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1879406818303424-gr2.jpg)
Oncologists' perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer - ScienceDirect
![Comprehensive Geriatric Assessment in the Older Adult with Cancer: A Review - European Urology Focus Comprehensive Geriatric Assessment in the Older Adult with Cancer: A Review - European Urology Focus](https://www.eu-focus.europeanurology.com/cms/attachment/22b76ee9-8c64-42bc-919b-3981359a1324/gr1_lrg.jpg)
Comprehensive Geriatric Assessment in the Older Adult with Cancer: A Review - European Urology Focus
Use of a Chemotherapy Toxicity Prediction Tool to Decrease Risks for Hospitalization in Older Patients
Yale Cancer Center study demonstrates efficacy of risk calculator in treating geriatric patients with cancer < Yale School of Medicine
![The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients—Part I: Early-Stage Disease | Drugs & Aging The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients—Part I: Early-Stage Disease | Drugs & Aging](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40266-020-00748-z/MediaObjects/40266_2020_748_Fig2_HTML.png)
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients—Part I: Early-Stage Disease | Drugs & Aging
![Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer | Journal of Clinical Oncology Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.20.02063/asset/images/large/jco.20.02063ta1.jpeg)
Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer | Journal of Clinical Oncology
![Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer | Journal of Clinical Oncology Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.20.02063/asset/images/large/jco.20.02063ta5.jpeg)
Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer | Journal of Clinical Oncology
![What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper. - Abstract - Europe PMC What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5812308/bin/JOP.2017.026435ta2.jpg)